Dr. Baohui Han has devoted more than 40 years to the diagnosis, treatment, and clinical research of pulmonary diseases and lung cancer. He is one of the earliest experts in China to pioneer targeted therapy for lung cancer, molecular epidemiology of lung cancer, and immunotherapy-based combination strategies. He previously conducted postdoctoral research in tumor immunotherapy at the Cancer Institute of the University of Pittsburgh Medical Center, and upon returning to China, he continued to focus on precision diagnosis, differential diagnosis, multidisciplinary treatment, and biological immunotherapy and targeted therapy for lung cancer.
Dr. Han has led his team to complete more than one hundred clinical studies on novel lung cancer therapies, making significant contributions to the development of innovative anticancer drugs in China. His landmark studies—including the third-line treatment trial of the multi-target tyrosine kinase inhibitor anlotinib and the clinical research of a bevacizumab biosimilar—have driven major breakthroughs in lung cancer drug development. He has published over one hundred papers in top international journals such as New England Journal of Medicine, JAMA Oncology, and Lancet Oncology, and has served as chief editor of several major professional books, including Guidelines for the Diagnosis and Treatment of Lung Cancer.
Dr. Han has led major national scientific projects, received the State Council Special Allowance, and has been honored with numerous awards including the Chinese Medical Science and Technology Award, the Chinese Respiratory Physician Award, and the Chinese Pharmaceutical Association Science and Technology Innovation Award.









